CSIMarket
 


Biohaven Ltd   (BHVN)
Other Ticker:  
 
 

BHVN's Capital Expenditures Growth by Quarter and Year

Biohaven Ltd 's Capital Expenditures results by quarter and year




BHVN Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 0.30 0.05 20.12
III Quarter September 1.25 0.00 0.01 1.12
II Quarter June 0.60 21.88 0.47 21.77
I Quarter March 0.74 0.51 1.19 0.90
FY   2.59 22.69 1.72 43.91



BHVN Capital Expenditures third quarter 2023 Y/Y Growth Comment
Biohaven Ltd in the third quarter 2023 achieved Capital Expenditures of $ 1.25 millions compare to Capital Expenditures recorded in same quarter a year ago.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 104 other companies have achieved higher Capital Expenditures growth. While Biohaven Ltd ' s Capital Expenditures no change of % ranks overall at the positon no. 1969 in the third quarter 2023.




BHVN Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - 500 % -99.75 % 1126.83 %
III Quarter September - - -99.11 % -
II Quarter June -97.26 % 4555.32 % -97.84 % 1993.27 %
I Quarter March 45.1 % -57.14 % 32.22 % -41.18 %
FY   - 1219.19 % -96.08 % 942.99 %

Financial Statements
Biohaven Ltd 's third quarter 2023 Capital Expenditures $ 1.25 millions BHVN's Income Statement
Biohaven Ltd 's third quarter 2022 Capital Expenditures $ 0.00 millions Quarterly BHVN's Income Statement
New: More BHVN's historic Capital Expenditures Growth >>


BHVN Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - 400 % 1696.43 %
III Quarter September 108 % - -97.87 % -94.86 %
II Quarter June -18.92 % 4190.2 % -60.5 % 2318.89 %
I Quarter March 146.67 % 920 % -94.09 % -45.12 %
FY (Year on Year)   - 1219.19 % -96.08 % 942.99 %




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #105
Healthcare Sector #325
Overall #1969

Capital Expenditures Y/Y Growth Statistics
High Average Low
1643.8 % 315.52 % -97.64 %
(Mar 31 2021)   (Mar 31 2022)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #105
Healthcare Sector #325
Overall #1969
Capital Expenditures Y/Y Growth Statistics
High Average Low
1643.8 % 315.52 % -97.64 %
(Mar 31 2021)   (Mar 31 2022)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Biohaven Ltd 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
4173.63 % 566.27 % -100 %
(Jun 30 2022)  


BHVN's III. Quarter Q/Q Capital Expenditures Comment
Biohaven Ltd achieved in the III. Quarter 2023 below company average Capital Expenditures doubling of 108% quarter on quarter, to $ 1.25 millions.

Although the III. Quarter 2023 Capital Expenditures Q/Q growth was below the average of 566.27 %, it has been yet good story, as the III. Quarter improvement, eclipses the % growth in the III. Quarter 2022

Within Major Pharmaceutical Preparations industry 37 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Biohaven Ltd 's Capital Expenditures growth quarter on quarter, overall rank is 318.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #38
Healthcare Sector #75
Overall #318
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #38
Healthcare Sector #75
Overall #318
Capital Expenditures Q/Q Growth Statistics
High Average Low
4173.63 % 566.27 % -100 %
(Jun 30 2022)  


BHVN's III. Quarter Q/Q Capital Expenditures Comment
Biohaven Ltd achieved in the III. Quarter 2023 below company average Capital Expenditures doubling of 108% quarter on quarter, to $ 1.25 millions.

Even if the III. Quarter 2023 Biohaven Ltd 's performance was below the average of 566.27 %, this has been still encouraging news, as the current surge, eclipses the % Capital Expenditures growth in the III. Quarter 2022

Within Major Pharmaceutical Preparations industry 37 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Biohaven Ltd 's Capital Expenditures growth quarter on quarter, overall rank is 318.


Biohaven Ltd 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 2.88 $ 0.00 $ 0.00 $ 0.00 $ 5.83
Y / Y Capital Expenditures Growth (TTM) - - - - -73.26 %
Year on Year Capital Expenditures Growth Overall Ranking # 1967 # 279 # 1640 # 2279 # 2485
Seqeuential Capital Expenditures Change (TTM) - - - - -74.05 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1969 # 1 # 1467 # 2270 # 2899




Cumulative Capital Expenditures growth Comment


In the Healthcare sector 323 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 279 to 1967.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1643.8 %
315.52 %
-97.64 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 324
Overall # 1967

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1643.8 %
315.52 %
-97.64 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 325
S&P 500 # 1969
Cumulative Capital Expenditures growth Comment


In the Healthcare sector 323 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 279 to 1967.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1643.8 %
315.52 %
-97.64 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 324
Overall # 1967

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1643.8 %
315.52 %
-97.64 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 325
S&P 500 # 1969




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
BHVN's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for BHVN's Competitors
Capital Expenditures Growth for Biohaven Ltd 's Suppliers
Capital Expenditures Growth for BHVN's Customers

You may also want to know
BHVN's Annual Growth Rates BHVN's Profitability Ratios BHVN's Asset Turnover Ratio BHVN's Dividend Growth
BHVN's Roe BHVN's Valuation Ratios BHVN's Financial Strength Ratios BHVN's Dividend Payout Ratio
BHVN's Roa BHVN's Inventory Turnover Ratio BHVN's Growth Rates BHVN's Dividend Comparisons



Companies with similar Capital Expenditures doubling for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Encompass Health Corporation-0.54%$ -0.542 millions
Myriad Genetics Inc -1.13%$ -1.130 millions
Opgen inc -1.22%$ -1.220 millions
Avantor Inc -3.33%$ -3.333 millions
United Therapeutics Corporation-4.51%$ -4.506 millions
Enanta Pharmaceuticals Inc-4.80%$ -4.802 millions
Davita Inc -5.46%$ -5.463 millions
Science 37 Holdings Inc -5.63%$ -5.630 millions
Cutera Inc -5.71%$ -5.708 millions
Zoetis Inc -5.84%$ -5.844 millions
U S Physical Therapy Inc-6.25%$ -6.248 millions
Generation Bio Co -6.30%$ -6.298 millions
Ngm Biopharmaceuticals Inc -6.45%$ -6.452 millions
Becton Dickinson And Company-6.67%$ -6.667 millions
3m Company-6.90%$ -6.897 millions
Apyx Medical Corporation-7.45%$ -7.447 millions
Edwards Lifesciences Corporation-7.68%$ -7.679 millions
Viatris Inc -7.70%$ -7.700 millions
Luna Innovations Inc-8.23%$ -8.232 millions
Nevro Corp -8.38%$ -8.377 millions
Shockwave Medical Inc -8.65%$ -8.649 millions
Sonendo Inc -8.86%$ -8.861 millions
Charles River Laboratories International inc -8.90%$ -8.904 millions
Nautilus Biotechnology Inc -9.24%$ -9.242 millions
Harvard Bioscience Inc-9.28%$ -9.276 millions
Fulgent Genetics Inc -9.42%$ -9.420 millions
Idexx Laboratories Inc-9.53%$ -9.529 millions
Sage Therapeutics Inc -9.89%$ -9.890 millions
Caredx Inc -10.40%$ -10.400 millions
Quest Diagnostics Inc-11.02%$ -11.017 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com